These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28917380)

  • 21. Dopamine agonist-induced Othello’s syndrome (delusional jealousy).
    Pírez-Mora G; Guilabert-Vidal M; Quintanilla-López MÁ
    Actas Esp Psiquiatr; 2015; 43(1):32-4. PubMed ID: 25665978
    [No Abstract]   [Full Text] [Related]  

  • 22. Dangerous passion: Othello syndrome and dementia.
    Cipriani G; Vedovello M; Nuti A; di Fiorino A
    Psychiatry Clin Neurosci; 2012 Oct; 66(6):467-73. PubMed ID: 23066764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Othello syndrome; a study in the psychopathology of sexual jealousy.
    TODD J; DEWHURST K
    J Nerv Ment Dis; 1955 Oct; 122(4):367-74. PubMed ID: 13307271
    [No Abstract]   [Full Text] [Related]  

  • 24. A Bayesian predictive processing account of Othello syndrome in Parkinson's disease.
    Foley JA; Chen C; Paget A; Cipolotti L
    Cogn Neuropsychiatry; 2023 Jul; 28(4):269-284. PubMed ID: 37366042
    [No Abstract]   [Full Text] [Related]  

  • 25. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.
    van Laar T; Postma AG; Drent M
    Parkinsonism Relat Disord; 2010 Jan; 16(1):71-2. PubMed ID: 19524477
    [No Abstract]   [Full Text] [Related]  

  • 26. [Addictions, drives and Parkinson's disease].
    Azulay JP
    Rev Neurol (Paris); 2008 Apr; 164(4):308-9. PubMed ID: 18439922
    [No Abstract]   [Full Text] [Related]  

  • 27. [Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
    Bailbé M; Karolewicz S; Neau JP; Dumas P; Gil R;
    Rev Neurol (Paris); 2002 Feb; 158(2):203-10. PubMed ID: 11965176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Executive task performance under deep brain stimulation of the subthalamic nucleus in Parkinson's disease revisited: the modulating influence of apathy, depression and mood].
    Lueken U; Stankevich Y; Goschke T; Schläpfer TE; Koy J; Reichmann H; Storch A; Wolz M
    Fortschr Neurol Psychiatr; 2014 Jul; 82(7):386-93. PubMed ID: 25014201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuropsychiatric disorders in early untreated Parkinson's disease.
    Starkstein SE
    J Neurol Neurosurg Psychiatry; 2009 Aug; 80(8):830. PubMed ID: 19608781
    [No Abstract]   [Full Text] [Related]  

  • 30. Pimavanserin approved for Parkinson's-related hallucinations, delusions.
    Traynor K
    Am J Health Syst Pharm; 2016 Jun; 73(12):853. PubMed ID: 27261226
    [No Abstract]   [Full Text] [Related]  

  • 31. Relation of lead trajectory and electrode position to neuropsychological outcomes of subthalamic neurostimulation in Parkinson's disease: results from a randomized trial.
    Witt K; Granert O; Daniels C; Volkmann J; Falk D; van Eimeren T; Deuschl G
    Brain; 2013 Jul; 136(Pt 7):2109-19. PubMed ID: 23801735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Othello syndrome. Preventing a tragedy when treating patients with delusional disorders.
    Miller MA; Kummerow AM; Mgutshini T
    J Psychosoc Nurs Ment Health Serv; 2010 Aug; 48(8):20-7. PubMed ID: 20669866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Behavioral disorders in Parkinson's disease: from pathophysiology to the mastery of dopaminergic treatment].
    Thobois S; Ardouin C; Schmitt E; Lhommée E; Klinger H; Xie J; Lagrange C; Kistner A; Aya Kombo M; Fleury V; Poisson A; Fraix V; Broussolle E; Pollak P; Krack P
    Rev Neurol (Paris); 2010 Oct; 166(10):816-21. PubMed ID: 20739041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case of hedonistic homeostatic dysregulation.
    Kessel BL
    Age Ageing; 2006 Sep; 35(5):540-1. PubMed ID: 16799178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pain is common in Parkinson's disease.
    Hanagasi HA; Akat S; Gurvit H; Yazici J; Emre M
    Clin Neurol Neurosurg; 2011 Jan; 113(1):11-3. PubMed ID: 20800342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behavioral, neuropsychiatric and cognitive disorders in Parkinson's disease patients with and without motor complications.
    Solla P; Cannas A; Floris GL; Orofino G; Costantino E; Boi A; Serra C; Marrosu MG; Marrosu F
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1009-13. PubMed ID: 21324349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlates of excessive daytime sleepiness in Parkinson's disease.
    Wegelin J; McNamara P; Durso R; Brown A; McLaren D
    Parkinsonism Relat Disord; 2005 Nov; 11(7):441-8. PubMed ID: 16154796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatments for Parkinson's disease.
    Health News; 2000 Jun; 6(6):8. PubMed ID: 10865523
    [No Abstract]   [Full Text] [Related]  

  • 39. [Parkinson's disease on the advance].
    Ceballos-Baumann A
    MMW Fortschr Med; 2009 Mar; 151(13):61-4. PubMed ID: 19504822
    [No Abstract]   [Full Text] [Related]  

  • 40. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.